Lin Zhang

Lin Zhang practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Lin Zhang's NPI, 1245215946, was assigned on December 14, 2005. Lin Zhang graduated from Beijing Medical University in 1984. Lin Zhang's California license number on file is A73655.

Lin Zhang's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Lin Zhang's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. The medical group on file is UC Davis Medical Group. Dmand AI also links Lin Zhang to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Lin Zhang practices, 3 sites in all. Vendor and product names are available with a free account.

Neurology is Lin Zhang's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Lin Zhang is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Lin Zhang's licenses on file in 2 states: California and New York.

Dmand AI lists encephalopathy, essential tremor, fibromyalgia and chronic pain, hereditary polyneuropathy, mobility impairment, muscle disease, neck pain and spine problems and neuropathy among the conditions Lin Zhang treats.

CMS data shows 1,897 Medicare services from Lin Zhang across 19 procedure codes in 2024, for 372 Medicare patients. Medicare paid $109,043 for them.

CMS counts 372 Medicare patients who saw Lin Zhang in 2024. The largest group is 75 to 84, with 136 patients. 66% of them have high blood pressure, and 64% have high cholesterol. 30% are also on Medicaid. Their average risk score is 1.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Lin Zhang's median patient age at 70, with 54% women.

In 2024, Lin Zhang wrote 3,328 Medicare Part D claims for 308 patients. 71% of them were for generic drugs. CMS names the drug for 3,153 of them, across 58 drugs with 11 or more claims each, at $3,381,655 in total drug cost. In 2023, CMS named 2,750 claims across 55 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Lin Zhang for performance year 2024, reported as part of a group. Lin Zhang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Lin Zhang as offering telehealth. CMS counts 76 procedures of skin biopsy by Lin Zhang, more than 73% of the clinicians it reports for that procedure.

Dmand AI links 214 papers to Lin Zhang, published from 2003 to 2025. 2020 was the busiest year, with 15. The most frequent topics are Cell Line, Tumor, Apoptosis and Gene Expression Regulation, Neoplastic. Lin Zhang has published most often in Cancer Res. Lin Zhang's most frequent co-authors are Randi Jenssen Hagerman, MD, John Michael Olichney, MD and Deborah A. Hall, MD.

Dmand AI links Lin Zhang to 1 clinical trial. Conditions studied include Huntington Disease and Chorea.

CMS Open Payments shows 1,232 general payments to Lin Zhang from 34 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 57% of the total. MDD US Operations, LLC paid the most, $418,631. It also lists 1 research payment totaling $220 in 2020.

Dmand AI lists 1 award for Lin Zhang, most recently CMS Stage 1 EHR in 2012.

Lin Zhang graduated from Beijing Medical University in 1984. Lin Zhang is a member of AAN.

Lin Zhang is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.